GeneDx Holdings Corp - Ordinary Shares - Class A

GeneDx Holdings Corp - Ordinary Shares - Class A

WGS

Get informed when a big investor buys or sells

+ Follow
Market Cap$2.57B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
GeneDx Holdings Corp - Ordinary Shares - Class AGeneDx Holdings Corp - Ordinary Shares - Class A-23.7--44%5.80.7
$77.75

Target Price by Analysts

11% downsideGeneDx Holdings Target Price DetailsTarget Price
$-140.29

Current Fair Value

260.5% downside

Overvalued by 260.5% based on the discounted cash flow analysis.

Share Statistics

Market cap$2.57 Billion
Enterprise Value$2.68 Billion
Dividend Yield$- (-)
Earnings per Share$-0.73
Beta1.98
Outstanding Shares29,710,139

Return

Return on Equity-43.55%ROE
Return on Assets-22.09%
Return on Invested Capital-16.55%

Valuation & Multiples

P/E Ratio-23.72P/E Ratio
PEG8.98PEG
Price to Sales5.83Price to Sales
Price to Book Ratio10.92Price to Book Ratio
Enterprise Value to Revenue5.9
Enterprise Value to EBIT-39.82
Enterprise Value to Net Income-26
Total Debt to Enterprise0.06
Debt to Equity0.69Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 4, 2026
EPS Estimate
$-0.19
Average shareholder expectation
Revenue Estimate
$111.01 M
Average shareholder expectation

Next Earnings Call

Expected Date
October 27, 2026
EPS Estimate
$0.07
Average shareholder expectation
Revenue Estimate
$122.98 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.3541 11.72%
Total Calls838,400 101.83%
Total Puts296,900 51.63%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %113.32% 6.78%
Total Invested$2.20B 9.59%
Investors Holding239 14.00%

ESG Score

No data

About GeneDx Holdings Corp

3 employees

Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and g...